Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OWCP NEWS ~~~ Date: May 31, 2017
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
follow OWCP on Twitter
https://twitter.com/OWCPharma
The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market
PETACH TIKVA, Israel, May 31, 2017 - OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.
Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.
Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We are looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany.
Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."
Alon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, "The German market is a great opportunity for OWCP.
Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country's healthcare system. mediq is a great partner for OWCP, and we're looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP's cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country."
About OWCP's Active Cannabinoid-Based Psoriasis Cream
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
OWCP has developed a proprietary active cannabinoid-based topical cream for psoriasis management, with the objective of reducing the skin dryness of patients suffering from the disease. The Company previously reported trial results that concluded that after application of the Company's active cannabinoid-based topical cream formulation, there was up to a 70% improvement in a variety of inflammation markers directly associated with psoriasis.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About mediq Innovation Experts
Frankfurt, Germany-based mediq Innovation Experts (mediq) has vast experience in the European healthcare market. Over the past ten years mediqhas successfully introduced disruptive technologies and services throughout the continent. The company's deep understanding of the market dynamics, regulatory, and reimbursement structures is a benefit in enabling international healthcare companies to develop European implementation strategies.
mediq's core capabilities include market assessment, strategy development, clinical validation, scientific marketing strategy, and marketing channel development. For more information visit http://innovationexperts.de.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
Mordechai Bignitz Chairman and CEO
Email: mordechai.bignitz@owcpharma.com
Tel: +972-(0)3-770-8526
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
UPDATED May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
$OWCP Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries.
Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12098812
$OWCP NEWS ~~~ Date: May 31, 2017
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market
PETACH TIKVA, Israel, May 31, 2017 - OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.
Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.
Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We are looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany.
Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."
Alon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, "The German market is a great opportunity for OWCP.
Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country's healthcare system. mediq is a great partner for OWCP, and we're looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP's cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country."
About OWCP's Active Cannabinoid-Based Psoriasis Cream
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
OWCP has developed a proprietary active cannabinoid-based topical cream for psoriasis management, with the objective of reducing the skin dryness of patients suffering from the disease. The Company previously reported trial results that concluded that after application of the Company's active cannabinoid-based topical cream formulation, there was up to a 70% improvement in a variety of inflammation markers directly associated with psoriasis.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About mediq Innovation Experts
Frankfurt, Germany-based mediq Innovation Experts (mediq) has vast experience in the European healthcare market. Over the past ten years mediqhas successfully introduced disruptive technologies and services throughout the continent. The company's deep understanding of the market dynamics, regulatory, and reimbursement structures is a benefit in enabling international healthcare companies to develop European implementation strategies.
mediq's core capabilities include market assessment, strategy development, clinical validation, scientific marketing strategy, and marketing channel development. For more information visit http://innovationexperts.de.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
Mordechai Bignitz Chairman and CEO
Email: mordechai.bignitz@owcpharma.com
Tel: +972-(0)3-770-8526
The Medical Cannabis Market Continues to Grow
FinancialBuzz.com News Commentary
NEW YORK, May 2017 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
On April 5, 2017, the company announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announce positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis.
OWCP's scientific team previously reported trial results and concluded that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis.
stay tuned
May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
today May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED May 30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED today May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
New videos added by OWC Board of Advisor
https://www.jeffreyfriedland.com/videos
OWCP Board of Advisor Jeffrey Friedland on Cannabis new Video
UPDATED a May27th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED today May27th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED May27th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED May26th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
Soon I hear
June !!!
KPAY News $KPAY ..May 23rd
https://finance.yahoo.com/news/former-vice-chairman-nasdaq-david-110000848.html
OWC owns the Patent period
Great 10Q.... ready to run again soon
I got this response from Israel
At this time Owcp is busy with the following things :
1. Complete implementing the pre-clinical efficacy study into the patent , so we will have a solid un breakable patent .
( as we stated we are taking the necessary actions to protect our IP)
2. Continue the professional dialogues with all the companies/ institutions that understood our finding and want to do business with us ( as we stated " world wide interest ")
3. Completing the , first ever and only, safety clinical study , under IRB APPROVAL, for our topical cream
And perhaps Jeff Friedland will help us on upcoming conferences and Industry events
More to follow soon
Thanks for your continued confidence and support
...
LOTE is Now Current
https://finance.yahoo.com/news/lote-current-otc-markets-122900101.html
KPAY NEWS MAY 5TH 2017 KinerjaPay Corp. Partners With PT 24 Jam Online, Parent Company Of UniPin Gaming PlatformFont
8:00 AM ET 5/5/17 | Dow Jones
Company Will Earn Commission On Every Game Voucher Purchased Through The KinerjaPay Website And Applications
JAKARTA, Indonesia, May 5, 2017 /PRNewswire/ --
KinerjaPay Corp., (OTCQB: KPAY), a digital payment and ecommerce platform, ("KinerjaPay" or the "Company") today announced a partnership with PT 24 Jam Online, parent company of UniPin, one of Indonesia's leading gaming platforms.
UniPin gives paid subscribers online and mobile access to more than 5,000 game titles on a variety of platforms, including Facebook, Google Play, Steam Wallet and Garena, through a single account. Currently, UniPin has more than 1.5 million paid users throughout Indonesia.
According to the terms of the agreement, consumers can purchase UniPin gaming vouchers across the KinerjaPay platform, and the Company will earn a commission on every transaction.
Indonesia is the fourth most populous country in the world. With one of that largest smartphone markets worldwide -- and the largest in South East Asia - its mobile gaming market is thriving. Analysts estimate that more than the 30 million consumers are active gamers, and nearly half of them regularly pay to play games.
Edwin Ng, Chairman and CEO for KinerjaPay Corp., commented on the announcement, "This relationship represents a substantial prospect for revenue growth. Not only will we generate commission on transactions executed through the KinerjaPay platform, we also have the opportunity to cross market our other services to UniPin's 1.5 million paid subscribers. As they are already comfortable conducting financial transactions across applications, I expect they will be inclined to adopt our platform for other transactions."
About KinerjaPay
KinerjaPay enables consumers to "Pay, Play and Buy" through its secure web portal and mobile applications. Based in Indonesia, the Company provides easy and convenient payment solution while shopping online at its marketplace platform. With its current omni-channel platform, users can perform various payment services such as credit card bill payment, utility, phone bill, healthcare insurance and direct transfer to anyone at their convenience. KinerjaPay is also planning to launch other eCommerce verticals such as travel market, delivery services, and online gaming in the near future. The Company's services are available through its mobile applications and on its website at http://www.kinerjapay.com.
About UniPin
UniPin gives paid subscribers online and mobile access to more than 5,000 game titles on a variety of platforms, including Facebook, Google Play, Steam Wallet and Garena, through a single account. Currently, UniPin has more than 1.5 million paid users throughout Indonesia. For more information, visit http://www.unipin.com
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about KPAY's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, KPAY or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by KPAY with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of KPAY's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause KPAY's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause KPAY 's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in KPAY 's filings with the SEC. In addition, KPAY operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. KPAY does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our securities which are included in our Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission on February 11, 2016.
For more information, please visit our website http://www.kinerjapay.co. There you will find access to all of our past press releases and SEC filings regarding the activities discussed in this letter.
Media Contact:
KinerjaPay Corp.
Email: info@kinerjapay.co
+62-8229-777-0098
SOURCE KinerjaPay Corp.
> Dow Jones Newswires
May 05, 2017 08:00 ET (12:00 GMT)
UPDATED May 3rd $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/khb8x7w
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
Dr Baruch "this unique study, which we designed to pursue and secure FDA orphan designation status," will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
https://finance.yahoo.com/news/owc-pharmaceutical-research-announces-multiple-110000088.html
$OWCP - OWC Pharma Announces New Multiple Myeloma
[Cancer Research] Study
https://t.co/FrF2erSQUA
#MedicalMarijuana
New IDM Corp presentation
http://www.idmmining.com/_resources/presentation/IDM-MINING-March-2017.pdf
$KPAY adds 23,000 new Locations with new Convenience Store Chain Partnership
http://finance.yahoo.com/news/kinerjapay-corp-partners-two-indonesias-120000634.html KPAY
#Indonesia
#mobilepayments
$LOTE secures Innovative Pilot with the Santa Monica Utility District
OLLAND, Conn., April 25, 2017 /PRNewswire/ -- Lot 78, Inc. (LOTE), Lot 78, Inc.'s Juice Bar Electric Vehicle Charger (www.juicebarev.com) was chosen as supplier for a SMUD (Santa Monica Utility District) electric vehicle charging station pilot project, slated for a term of 5 years with an option to renew for an additional 5 years. Juice Bar's Mini Bar Double Level 2 electric vehicle charging station met the requirements as part of the RFP, and was chosen based on their ability to meet and deliver the services required.
LOTE CEO David Schmid, "Our Juice Bar Electric Vehicle Charger is excited and honored to be associated with world class utility providers such as the Santa Monica Utility District. Part of our tiered go to market strategy includes working alongside Utility Companies to promote sustainable urban mobility. Pilot program awards such as this one validate our product's competitiveness in the marketplace."
SMUD is the nation's sixth largest community owned electric service provider, providing electricity for more than 65 year to Sacramento County. Servicing an area that has a population of 1.4 million, with 624,770 residents and business accounts SMUD is a recognized industry leader and award winner for its innovative energy efficiency programs, renewable power technologies, and for its sustainable solutions for a healthier environment.
ABOUT LOT 78, INC. The Company was incorporated in the State of Nevada on June 27, 2008. On March 14, 2011, the Company filed a Certificate of Amendment with the Secretary of State of Nevada changing the name of the Company to "Bold Energy, Inc." On November 12, 2012, the Company, then under the name Bold Energy, Inc., entered into a Share Exchange Agreement with Anio Limited a limited liability company established under the laws of the United Kingdom ("Anio Ltd."), which conducts its primary line of business under the name Lot78, Inc., the shareholders of Anio Ltd., and the controlling stockholders of the Company. The company changed names to Lot78, Inc. on January 31, 2013. On July 15, 2016, the Company entered into a Letter of Intent to merge with Compound Holdings, LLC, a Connecticut limited liability company. Subsequently, on July 18, 2016, the Company and Compound Holdings LLC entered into a definitive Agreement and Plan of Merger. Pursuant to the plan of merger, upon closing, the Company intends to change its name to Compound Holdings, Inc.
$KPAY NEW WEB SITES http://www.kinerjapay.co
and
http://www.kinerjapay.com
KPAY
ON CNBC !!! The country’s first drive-through marijuana shop is opening in Colorado
http://wapo.st/2pFhqUP?tid=ss_tw
OWCP $OWCP
#MedicalMarijuana #Marijuana
UPDATED April 21st $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/lnyuzoq
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases P[color=red]romising Preliminary Results [70%] From Efficacy Tests [/color]of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
OWCP #OWCP $OWCP
His shares would be certainly restrictied for 6 months